Ligand Prices Upsized $625M Convertible Notes Offering with 27.5% Premium
LGND has more than doubled off its 52-week low of $110 on elevated volume (3.5× avg).
Summary
Ligand has priced an upsized $625 million offering of 0% convertible senior notes due 2031, an increase from the initially proposed $550 million. The offering, which follows the proposed announcement yesterday, is expected to generate $605.3 million in net proceeds. These funds will be used for general corporate purposes, including potential investments and to support the recently announced $739 million XOMA Royalty acquisition. The notes feature an initial conversion price of $334.27, a 27.5% premium over the prior day's closing price, and the company plans to repurchase $60 million of its common stock, mitigating immediate dilution.
At the time of this announcement, LGND was trading at $267.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $110.00 to $276.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.